Featured Jobs
|
Retirement Relationship Manager MAP Retirement
|
|
Regional Vice President, Sales MAP Retirement
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
|
MAP Retirement
|
|
3(16) Retirement Plan & Customer Liaison Compass
|
|
Pattison Pension
|
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
|
DWC - The 401(k) Experts
|
|
BPAS
|
|
MAP Retirement
|
|
Sentinel Group
|
|
Pension Investors Corporation
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
Cost of Generic Drug Development and Approval
Assistant Secretary for Planning and Evaluation [ASPE], U.S. Department of Health and Human Services [HHS] 
Feb. 3, 2022 "This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets. The developed framework forms the basis for an accompanying operational model that enables the user to specify numerous details of a generic drug development project and provides cost, revenue, and ENPV estimates for the project being examined." |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |